Antithyroid drug-induced agranulocytosis by Lee, CH & Liang, RHS
Title Antithyroid drug-induced agranulocytosis
Author(s) Lee, CH; Liang, RHS
Citation Hong Kong Medical Journal, 1999, v. 5 n. 4, p. 394-396
Issued Date 1999
URL http://hdl.handle.net/10722/162359
Rights Creative Commons: Attribution 3.0 Hong Kong License
394      HKMJ Vol 5 No 4 December 1999
Lee et al
Introduction
Thyrotoxicosis is a common endocrine disorder. It
affects mainly women of child-bearing age (prevalence,
approximately 2%)1 and is approximately five times
more common in females than in males. Patients
are usually treated with antithyroid drugs, the most
common of which is carbimazole. Antithyroid drug
therapy, however, is associated with a potentially fatal
complication—namely, agranulocytosis. The incidence
of this particular side effect has been reported to
range from 0.3% to 0.6%.2 Although antithyroid drug–
induced agranulocytosis is rare, it has been associated
with a mortality rate of 21.5%.3 We report on two
thyrotoxic patients who presented with fever after
having taken antithyroid drugs.
Case reports
Case 1
A 36-year-old woman with thyrotoxicosis presented
to the Queen Mary Hospital (QMH) in November 1994
with a fever (temperature, 38.5°C) and a sore throat
after having taken carbimazole 10 mg three times daily
for 1 month. The white blood cell count at the time of
the patient’s hospital admission was 0.6x109 /L (normal
range, 3.2-9.8 x 109 /L) and the neutrophil count was
0.03x109 /L. Intravenous imipenem was given with one
dose of granulocyte colony-stimulating factor (GCSF)
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300 µg subcutaneously on the day of admission. The
patient’s white blood cell count increased to 1.6x109 /L
(neutrophils, 0) on day 2 and her temperature increased
to 40°C. During the next few days, the white blood
cell and neutrophil counts increased gradually. On
day 4 of hospital admission, the white blood cell count
was 4.4x109 /L (neutrophils, 0.68x109 /L) and the
patient became afebrile. She was discharged home on
day 7 with white blood cell and neutrophil counts
of 4.1x109 /L and 0.80x109 /L, respectively, and she
remained afebrile. Tests for micro-organisms gave
negative results.
Case 2
A 40-year-old woman presented to the Accident and
Emergency Department of the QMH in May 1998 with
a fever. Thyrotoxicosis had been diagnosed 3 months
previously, for which the patient had started a course
of a propylthiouracil, but changed to carbimazole
after 2 weeks because of gastro-intestinal disturbance.
On this occasion, she was discharged home and was
given oral antibiotics. She was subsequently admitted
to the QMH because of persistent fever, and chest and
urinary symptoms. The patient’s white blood cell count
at the time of hospital admission was 0.44x109 /L
(neutrophils, 0) and her temperature was 39°C. Bone
marrow examination showed normocellular marrow
and a selective suppression of myelopoiesis. These
symptoms were clinically compatible with a diagno-
sis of antithyroid drug–induced agranulocytosis. The
patient was given GCSF 300 µg twice daily, followed
by subcutaneous GCSF 300 µg/d and intravenous
ceftazidime and amikacin. Oral itraconazole was also
given on day 2 because of persistent fever. The white
blood cell count increased gradually to 1.7x109 /L
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(neutrophils, 0.45x109/ L) on day 3 of hospital admis-
sion and eventually increased to 11.8x109 /L (neutro-
phils, 9.80x109 /L) on day 4, when GCSF treatment
was discontinued. The patient became afebrile and tests
for micro-organisms gave negative results.
Discussion
The two patients described in this report presented
with antithyroid drug–induced agranulocytosis. This
is a very rare complication of the use of a commonly
prescribed drug. Antithyroid drug–induced agranulo-
cytosis is diagnosed when there is a compatible
clinical history, an absolute neutrophil count of
0.5x109 /L or less, and bone marrow histological
features consistent with agranulocytosis.4 The diagno-
sis is not applicable to patients who have neutro-
penia due to chemotherapy, or patients with chronic
neutropenia, including congenital and chronic auto-
immune neutropenia.
The immune-mediated destruction of mature
neutrophils was the first mechanism to be identified
as a cause of antithyroid drug–induced agranulo-
cytosis.4 Sprikkelman et al4 have described four
different immunological mechanisms that may be
responsible. Firstly, antibodies may develop against
the antithyroid drug when it is bound to the cell mem-
brane of the granulocyte, resulting in an accelerated
destruction of the granulocyte. Secondly, antibodies
may target the drug/metabolite complex that has been
adsorbed to the neutrophil granulocyte in the presence
of plasma component. Thirdly, the drug may trigger
the production of auto-antibodies. Finally, the inter-
action of a granulocyte antigen and drug may induce
the production of antibodies. Besides these mecha-
nisms, idiosyncratic drug-induced agranulocytosis,
which is a severe selective depression of myelopoiesis
due to an unpredictable adverse reaction to a wide
variety of drugs in hypersensitive individuals, has also
been a postulated mechanism for agranulocytosis, as was
documented for the second patient of this case report.
Drug-induced agranulocytosis usually occurs
within 1 to 2 months of taking the antithyroid drug,
but the onset of the disease can also be delayed, as
was the case for the second patient. It has been
reported that the white blood cell count usually spon-
taneously returns to normal over a period of 1 to 2
weeks after discontinuing treatment with the offend-
ing drug; the time taken ranges from 7 to 56 days.1,5
The speed of neutrophil recovery depends on the
number of myeloid precursor cells that are present in
the bone marrow. Recovery may be prolonged if there
is granulocyte precursor aplasia. Previous reports have
suggested that giving GCSF can hasten the marrow
recovery to approximately 1 week.1,5 This suggestion
was confirmed in the two patients presented here; both
patients’ white blood cell count returned to within the
normal range by day 4 of GCSF treatment. At the
QMH, treatment is arbitrarily discontinued when the
absolute neutrophil count is  1.0x109 /L or higher, since
the optimal duration of GCSF therapy for agranulo-
cytosis is currently unknown. Only a single dose of
GCSF was used in the first patient. In contrast, GCSF
treatment was stopped when the neutrophil count
was higher than 0.5x109 /L in the second patient. The
initial dose of GCSF used in the second patient was
double that used in the first patient. The usual recom-
mended dosage of GCSF is 5 µg·kg-1·d-1, although there
is no large randomised controlled trial that compares
effects of giving other dosages.
Agranulocytosis had a poor prognosis in the past,
with a reported mortality rate of 21.5%.3 The mortality
rate has decreased significantly in the past two decades
because of the availability of potent antibiotics. The
prognosis depends on a variety of factors, such as
age, co-morbidity, immediate antibiotic treatment, and
duration of severe granulocytopenia. Successful treat-
ment of antithyroid drug–induced agranulocytosis by
GCSF has been reported in the literature.1,6 A mortal-
ity rate of 5% has been reported for 58 patients with
severe agranulocytosis who were treated with GCSF.4
These data indicate that GCSF enhances the recovery
of the peripheral blood granulocytic lineage, which
results in a faster normalisation of the peripheral
blood granulocyte count, as well as a reduced inci-
dence of fatal complications. This treatment has been
recommended for most circumstances, and GCSF has
been purified, molecularly cloned, and expressed as
a recombinant protein.7 It is a potent stimulus for
normal neutrophil proliferation and maturation in vitro
and in vivo. Other approved indications include
idiopathic aplastic anaemia, idiopathic neutropenia,
and chemotherapy-associated agranulocytosis.
Antithyroid drug–induced agranulocytosis is diag-
nosed at the QMH by paying careful attention to the drug
history of patients who present with fever. Not all pa-
tients with agranulocytosis have fever or other symptoms
of infection, however, and some patients can be totally
asymptomatic. Tajiri et al7 have suggested that continu-
ing antithyroid drug treatment in patients with asymp-
tomatic agranulocytosis might actually cause permanent
damage to the marrow. This suggestion raises the impor-
tant issue of regularly monitoring the white blood cell
count in patients who are taking antithyroid drugs.7
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Asawa et al8 have recommended that the leukocyte
differential count be checked, as patients with a normal
white blood cell count may have a low neutrophil count.8
The practical difficulty, however, is that thyrotoxicosis
is a very common disease and hence many patients take
antithyroid drugs. In addition, the white blood cell count
can be falsely reassuring if normal, or unnecessarily
worrisome if relatively low. It is therefore more practical
and more cost-effective for doctors to instruct patients
who are taking antithyroid drugs to have their white
blood cell count checked if they have a fever or sore
throat, rather than to have routine regular monitoring.9
Doctors should also have a high index of suspicion of
agranulocytosis when they encounter such patients.
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